Last reviewed · How we verify
polyene phosphatidylcholine
Polyene phosphatidylcholine is a type of lipid that may help restore the integrity of cell membranes.
Polyene phosphatidylcholine is a type of lipid that may help restore the integrity of cell membranes. Used for Treatment of severe infections, particularly those caused by fungal pathogens.
At a glance
| Generic name | polyene phosphatidylcholine |
|---|---|
| Also known as | PPC, AYP-101 1, AYP-101 2, Placebo, AYP-101 |
| Sponsor | Institute of Hematology & Blood Diseases Hospital, China |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | Phase 3 |
Mechanism of action
It does this by incorporating into the cell membrane and stabilizing it, potentially reducing the permeability of the membrane to toxins. This can be particularly beneficial in cases where the cell membrane has been compromised, such as in certain types of infections or diseases.
Approved indications
- Treatment of severe infections, particularly those caused by fungal pathogens
Common side effects
- Hypersensitivity reactions
Key clinical trials
- A Real World Study of Polyene Phosphatidylcholine Injection for the Prevention and Treatment of DILI in Patients With Malignant Hematological Diseases
- Evaluate Pharmacokinetic/Pharmacodynamic and Safety/Tolerability of AYP-101 in Healthy Subjects (PHASE1)
- Evaluate the Efficacy and Safety of AYP-101 for the Reduction of Submental Fat in Chin Area (PHASE3)
- A Study of Chiglitazar in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes Mellitus (PHASE2)
- Glucocorticoids for Acute Drug Induced Liver Injury With Hyperbilirubinemia (NA)
- F573 for Injection for the Treatment of Liver Injury/Failure (PHASE2)
- The Treatment of Liver Injury After Liver Resection With Polyene Phosphatidylcholine (PHASE4)
- Determine the Dosing Interval and Optimal Dose of AYP-101 for the Reduction of Submental Fat in Chin Area (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: